{"entity":{"id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","aka":["ProvONE"],"tldr":"A phase 2 trial of Sipuleucel-T in prostate cancer, run by Dendreon, now recruiting.","summary":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T is a phase 2 interventional study registered as NCT06134232 by Dendreon, with 400 participants planned, started 2023-10-02 and due to reach its primary completion in 2031-12-31. Interventions recorded: Sipuleucel-T Injection. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06134232","url":"https://clinicaltrials.gov/study/NCT06134232"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":["sipuleucel-t"],"companies":["dendreon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06134232","phase":"2","setting":"An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response","sponsor":"Dendreon","participation":[{"nct":"NCT06134232","source":"https://clinicaltrials.gov/study/NCT06134232","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"798297c8c4886620b8bf7bc55d78ca4c66c8e60972c2f092f0845ccfe897c245","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-27","leadSponsor":"Dendreon","collaboratorCount":2,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":31,"recruitingSiteCount":30,"countries":["United States"]}],"started":"2023-10-02","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06134232/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"drug":[{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/"}],"company":[{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/"}]}}